To assess the therapeutic potential of GPC2-targeted CAR T cells in DIPG, and to validate the target discovery pipeline, we selected the lowest-affinity GPC2 CAR construct to minimize on-target/off-tumor toxicity while maintaining tumor specificity19. Here, GPC2 is linked to neoplasm.